Overview
- Authors:
-
-
Kevin D. Altria
-
Pharmaceutical Development, Glaxo Wellcome R&D, Ware, Herts., UK
Access this book
Other ways to access
Table of contents (17 chapters)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back Matter
Pages 280-285
About this book
During the 1980's the analysis of pharmaceuticals was dominated by the use of High Perfor mance Liquid Chromatography (HPLC). Other separative techniques such as Gas Chromato graphy and Thin Layer Chromatography offered alternatives but their quantitative capabili ties and/or solute range could not approach that of HPLC. The majority of pharmaceuticals are ionic and it would be reasonable to assume that electrophoresis may be useful in the analysis of pharmaceuticals. However, the electrophore tic instruments available in the 1980's were labour intensive and employed post-separation detection procedures. During the late 1980's and early 1990's extensive research was con ducted into the possibilities of conducting electrophoretic separations in capillaries. This approach allowed on-line detection and could be performed on fully automated equipment. This research led to the advent of modern day capillary electrophoresis (CE) instruments which offer similar performance and automation levels to that of HPLC. Research was also focused on developing applications for CE and particular attention was paid to applications within the pharmaceutical analysis area. These applications proved that CE could be applied to a wide range of drug types including water insoluble and neutral compounds. The ability to achieve efficient chiral separations of drugs also increased the popularity of the technique. CE with indirect UV detection has become established as a simple and effective alternative to ion-exchange chromatography for the determination of small inorganic or organic ions.
Reviews
"Das Buch bietet dem pharmazeutischen Chemiker eine gute Übersicht über die Möglichkeiten, die Kapillarelektrophorese für pharmazeutische Analysen einzusetzen, aber sich auch über deren Grundlagen und Entwicklungsmöglichkeiten zu informieren." (Fresenius Journal of Analytical Chemistry Nr. 1/99)
Authors and Affiliations
-
Pharmaceutical Development, Glaxo Wellcome R&D, Ware, Herts., UK
Kevin D. Altria
About the author
Dr. Kevin D. Altria ist Wissenschaftler bei der Glaxo Company in Großbritannien.
The author, Dr. Kevin D. Altria, has been working in Glaxo Wellcome R & D for 10 years. During this time he has developed and implemented many routine pharmaceutical analysis CE methods.
